- Global Pharma News & Resources

Qiming's Portfolio Company Antengene Lists on Main Board of HKEX

SHANGHAI, Nov. 20, 2020 /PRNewswire/ -- Qiming's portfolio company Antengene (SEHK: 6996) officially listed on the Main Board of The Stock Exchange of Hong Kong Limited today. The issue price is HK$18.08 per share; the stock opens at HK$ 19.6 per share, up 8.41%, with a market cap of HK$ 13.097 billion.

Antengene public offering shares are oversubscribed for 264 times.

The listing of Antengene is the 11th successful public listing in our portfolio this year. Qiming started to invest in Antengene in August 2017 as the A round lead investor and followed on in its subsequent financing rounds.

Antengene is a leading clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. Antengenwe has industry-leading R&D capabilities and differentiated strategic approach to developing novel oncology therapies. The company's vision is to treat patients beyond borders and transform their lives by discovering, developing and commercializing global first-in-class, only-in-class and/or best-in-class therapies.

Antengene has built a highly selective pipeline of 12 drug assets focused on oncology, including two late-stage clinical assets, four early-stage clinical assets and six pre-clinical stage assets. The company also has nine ongoing clinical trials and five clinical trials planned for initiation, and received nine IND approvals in multiple jurisdictions across the APAC regions.

Antengene's management team has extensive experience in the commercialization of oncology drugs in the APAC region. The experienced commercial team to ensure the successful commercialization of the drug candidates upon approval.

"As the first institutional investor in Antengene, we have accompanied the company along with its growth. Dr. Jay Mei has a profound understanding of the research and clinical development of new drugs. The company achieved many milestones in the past three years and has established a distinguished pipeline. IPO might be a small milestone for an ambitious company. We wish the company greater achievement in the future," said William Hu, Managing Partner at Qiming Venture Partners.

About Qiming Venture Partners

Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Shenzhen, Hong Kong, Seattle, Boston and San Francisco Bay Area.

Currently Qiming Venture Partners manages nine US Dollar funds and six RMB funds with $5.6 billion assets under management. Since our establishment, we have invested in outstanding companies in the TMT and healthcare industries at the early and growing stages.

Since our debut, we have backed over 370 fast-growing and innovative companies. Over 120 companies are already listed on NYSE, NASDAQ, HKEx, Gretai Securities Market, Shanghai Stock Exchange and Shenzhen Stock Exchange, or achieved exit through M&A and other means. There are also over 30 portfolio companies that have achieved unicorn status.

Many of our portfolio companies are today's most influential firms in their respective sectors, including Xiaomi (SEHK:1810), Meituan (SEHK:3690), Bilibili (NASDAQ:BILI), Roborock (SHSE:688169), Gan & Lee (SHSE: 603087), Tigermed (SZSE:300347, SEHK:3347), Zai Lab (NASDAQ:ZLAB), Venus MedTech (SEHK:2500), CanSino (SEHK:6185, SHSE:688185), Schrödinger (NASDAQ:SDGR), Sanyou Medical (SHSE:688085), AmoyDx (SZSE:300685), Berry Genomics (SZSE:000710), SinocellTech (SHSE: 688520), WeDoctor Group, UBTech among many others.

SOURCE Qiming Venture Partners

Editor Details

Last Updated: 20-Nov-2020